Ruxolitinib bụ obere molekul Janus kinase inhibitor nke a na-eji na ọgwụgwọ nke etiti ma ọ bụ nnukwu ihe ize ndụ myelofibrosis na ụdị na-eguzogide ọrịa polycythemia vera na graft-vs-host.A na-ejikọta Ruxolitinib na obere oge na-adịkarị nwayọọ elu na serum aminotransferase n'oge ọgwụgwọ yana n'ọnọdụ ndị na-adịghị ahụkebe nke njedebe onwe onye, ​​​​ihe na-apụta n'ụlọ ọgwụ na-adịghị ahụkebe nke imeju imeju yana n'ọnọdụ nke ịmaliteghachi ịba ọcha n'anya B na ndị nwere ike.

Ruxolitinib bụ ihe mgbochi Janus-associated kinase (JAK) nke nwere ike ime antineoplastic na immunomodulating.Ruxolitinib na-ejikọ kpọmkwem ma na-egbochi proteintyrosinekinases JAK 1 na 2, nke nwere ike ibute mbelata mbufụt na mgbochi nke mgbasa cellular.Ụzọ JAK-STAT (transducer signal and activator of transcription) ụzọ na-arụ ọrụ dị mkpa n'igosipụta ọtụtụ cytokines na ihe ndị na-eto eto ma na-etinye aka na mgbasa ozi cellular, uto, hematopoiesis, na nzaghachi mgbochi;Enwere ike ịkwalite JAK kinases na ọrịa mkpali, ọrịa myeloproliferative, na ọrịa dị iche iche.

Ruxolitinib bụ apyrazoleDochiri na ọnọdụ 1 site na otu 2-cyano-1-cyclopentyethyl na ọnọdụ 3 site na otu pyrrolo [2,3-d] pyrimidin-4-yl.A na-eji ya dị ka nnu phosphate maka ọgwụgwọ ndị ọrịa nwere myelofibrosis nke etiti ma ọ bụ nnukwu ihe ize ndụ, gụnyere myelofibrosis nke mbụ, post-polycythemia vera myelofibrosis na post-dị mkpa thrombocythemia myelofibrosis.Ọ nwere ọrụ dị ka onye na-ahụ maka antineoplastic na EC 2.7.10.2 (protein na-abụghị nke a kapịrị ọnụ-tyrosinekinase) inhibitor.Ọ bụ nitrile, apyrrolopyrimidinena onye otu pyrazole.